Key terms

About WVE

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest WVE news

Mar 12 6:41am ET Wave Life Sciences price target raised to $19 from $10 at Mizuho Mar 11 2:40am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), MoonLake Immunotherapeutics (MLTX) and Wave Life Sciences (WVE) Mar 11 1:10am ET Analysts Are Bullish on These Healthcare Stocks: Wave Life Sciences (WVE), Dexcom (DXCM) Mar 07 9:31am ET Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE) Mar 07 6:06am ET Wave Life Sciences price target raised to $15 from $8 at H.C. Wainwright Mar 06 7:52am ET Wave Life Sciences Unveils New Corporate Presentation Mar 06 7:33am ET Wave Life Sciences reports Q4 EPS (15c), consensus (23c) Feb 27 8:49am ET Wave Life Sciences announces upcoming presentations at MDA conference Feb 02 11:07am ET Biotech Alert: Searches spiking for these stocks today Feb 01 1:18am ET Strategic Investment Boosts Wave Life Sciences: A Buy Rating Amidst Market Underappreciation Jan 22 3:20pm ET Salim Syed Endorses Wave Life Sciences with a Buy Rating on RNA Editing Therapies’ Potential Jan 11 1:40am ET Leerink Partners Sticks to Its Buy Rating for Wave Life Sciences (WVE) Jan 08 8:24am ET Wave Life Sciences: Selection of clinical candidate in obesity planned for Q3 Dec 19 6:13am ET Wave Life Sciences upgraded to Outperform from Market Perform at Leerink Dec 19 6:10am ET Wave Life Sciences upgraded to Outperform from Market Perform at Leerink Dec 19 4:15am ET Wave Life Sciences (WVE) Receives a Hold from Leerink Partners Dec 15 8:31am ET Wave Life Sciences announces initiation of dosing in Phase 2 FORWARD-53 trial

No recent news articles are available for WVE

No recent press releases are available for WVE

WVE Financials

1-year income & revenue

Key terms

WVE Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

WVE Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms